Report cover image

Turner Syndrome Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20146950

Description

Around 1 out of 2000 to 2500 live female births are affected by Turner syndrome. Studies reveal that there are nearly 70,000 females with Turner syndrome in the United States. It is reported that the frequency of the disorder is not influenced by racial and ethnic factors. Current therapies, such as growth hormone for height and estrogen replacement for puberty, do not address all the health issues faced by Turner syndrome patients. Thus, there is a need for drug pipeline expansion for the disorder to accommodate the diverse and complex needs of affected individuals.

Report Coverage

The Turner Syndrome Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into Turner syndrome drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Turner syndrome. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The Turner syndrome pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from Turner syndrome.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to Turner syndrome.

Turner Syndrome Drug Pipeline Outlook

Turner syndrome, also known as monosomy X, 45X, or Ullrich-Turner syndrome, is a rare genetic condition in which one of the X chromosomes in females is completely or partially missing. Common symptoms include a webbed neck, short stature, broad chest, and low-set ears, among others. This genetic disorder is considered the most common sex chromosomal abnormality in females, with the patients facing emotional and psychological challenges besides various co-morbid conditions.

Growth hormone therapy is often prescribed to increase height and is usually started in childhood. Estrogen replacement therapy in the form of pills, patches, or injections is given during the early teenage years to promote the development of secondary sexual characteristics. Increased emphasis on the development of drugs that can prevent or mitigate the onset of complications associated with Turner syndrome is expected to significantly improve the quality of life of the patients and also positively impact the disease pipeline landscape.

Turner Syndrome – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of Turner syndrome drugs based on several segmentations including:

By Phase
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class
  • Recombinant Fusion Proteins
  • Small Molecule
  • Monoclonal Antibody
  • Peptide
  • Polymer
  • Gene Therapy
By Route of Administration
  • Oral
  • Parenteral
  • Others
Turner Syndrome – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase III covers a major share of the total clinical trials for Turner syndrome.

Turner Syndrome – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under Turner syndrom pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptide, polymer, and gene therapy. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Turner syndrome.

Turner Syndrome Clinical Trials Therapeutic Assessment - Competitive Dynamics

The EMR report for the Turner Syndrome drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Turner syndrome clinical trials:
  • Novo Nordisk A/S
  • Ascendis Pharma Endocrinology Division A/S
  • Eli Lilly and Company
  • Merck KGaA
  • Ferring Pharmaceuticals
  • Genentech, Inc.
  • Sequenom, Inc.
  • LG Chem
Turner Syndrome - Emerging Drugs Profile

Major drugs currently in the drug pipeline are as follows:

Drug: Somapacitan

Sponsored by Novo Nordisk A/S, this Phase III study aims to evaluate the safety and efficacy of somapacitan, a new growth hormone medicine, in children either born small for gestational age or with Turner syndrome, idiopathic short stature, or Noonan syndrome. The study will span for a course of 3 years, with the administration of somapacitan once a week.

Biological: Lonapegsomatropin, Drug: Somatropin

The objective of this randomized, open-label, active-controlled clinical study is to examine the efficacy, safety, and tolerability of different dose levels of lonapegsomatropin (administered once a week) in comparison to daily somatropin in an estimated 48 prepubertal subjects with Turner syndrome. This Phase II clinical trial is conducted by Ascendis Pharma Endocrinology Division A/S.

Reasons To Buy This Report

The Turner Syndrome Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for Turner syndrome. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within Turner syndrome pipeline insights.

Key Questions Answered in the Turner Syndrome - Pipeline Insight Report
  • What is the current landscape of Turner syndrome pipeline drugs?
  • How many companies are developing Turner syndrome drugs?
  • How many phase III and phase IV drugs are currently present in Turner syndrome pipeline drugs?
  • Which companies/institutions are leading the Turner syndrome drug development?
  • What is the efficacy and safety profile of Turner syndrome pipeline drugs?
  • What are the opportunities and challenges present in the Turner syndrome drug pipeline landscape?
  • Which company is conducting major trials for Turner syndrome drugs?
  • What geographies are covered for Turner syndrome clinical trials?
  • What are emerging trends in Turner syndrome clinical trials?
Related Reports

Global Rare Diseases Treatment Market

Global Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Turner Syndrome Pipeline
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Types of Turner Syndrome
3.5 Diagnosis
3.6 Treatment
4 Patient Profile: Turner Syndrome Pipeline
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Turner Syndrome Pipeline: Epidemiology Snapshot
5.1 Turner Syndrome Pipeline Incidence by Key Markets
5.2 Turner Syndrome Pipeline – Patients Seeking Treatment in Key Markets
6 Turner Syndrome Pipeline: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Turner Syndrome Pipeline: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Turner Syndrome Pipeline, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Turner Syndrome Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Turner Syndrome Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: Somapacitan
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Drug: 17-beta estradiol
10.2.3 Other Drugs
11 Turner Syndrome Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Biological: Lonapegsomatropin, Drug: Somatropin
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Drug: Vosoritide
11.2.3 Other Drugs
12 Turner Syndrome Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug 1
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Turner Syndrome Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Turner Syndrome, Key Drug Pipeline Companies
14.1 Novo Nordisk A/S
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Ascendis Pharma Endocrinology Division A/S
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Eli Lilly and Company
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Merck KGaA
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Ferring Pharmaceuticals
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Genentech, Inc.
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Sequenom, Inc.
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
14.8 LG Chem
14.8.1 Company Snapshot
14.8.2 Pipeline Product Portfolio
14.8.3 Financial Analysis
14.8.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us